The association between the long-term use of proton pump inhibitors (PPIs) and the risks of
various diseases remains controversial. Therefore, the primary objective of this study was to …

The availability of over-the-counter (OTC) proton pump inhibitors (PPIs) for the short-term (2
weeks) management of frequent heartburn (≥ 2 days/week) has increased markedly, yet …

Background Gastroprotectant drugs are used for the prevention and treatment of peptic ulcer
disease and might reduce its associated complications, but reliable estimates of the effects …

Background and Aims Proton pump inhibitors (PPIs) have been associated with adverse
clinical outcomes amongst clopidogrel users after an acute coronary syndrome. Recent pre …

Angiogenesis contributes to the development of nonalcoholic steatohepatitis (NASH) and
promotes inflammation, fibrosis, and progression to hepatocellular carcinoma (HCC) …

Background Use of proton pump inhibitors (PPI s) has been associated with cardiovascular
disease amongst patients not on antiplatelet therapy. The associations of PPI use, duration …

Background Proton pump inhibitors (PPIs) are a commonly prescribed medication that
recent data has linked to an increased risk of cardiovascular morbidity and all cause …

Some things change. Much remains the same. Proton pump inhibitors (PPIs) continue to be
the mainstay of treatment of acid-related disease, especially gastroesophageal reflux …

The prevalence of abnormal acid gastroesophageal reflux (GER) is higher in patients with
idiopathic pulmonary fibrosis (IPF) than in matched control subjects. Several studies …

Background Clopidogrel's anti‐platelet effects may be attenuated by a pharmacokinetic
interaction with co‐prescribed proton pump inhibitors, which inhibit oxidative pathways that …